Challenge:
Alacrita provided interim chief medical officer support to an oncology company over the course of two years. The company was a developing a portfolio of first in class small molecules to treat a range of tumor types. Three of the products were in Phase I clinical trials, the first and most advanced was recruiting patients in a range of hematologic malignancies including acute myeloid leukemia, myeloid dysplastic syndrome and chronic lymphocytic leukemia. The second and third molecules were subject of Phase I/II trials in specific solid tumors. The company was well-capitalized with around 80 employees. The programs were discovered internally by the company’s cancer research efforts and were spearheading the company’s transition from a research-oriented biotech to a company focused on clinical development. The molecules, which targeted new cancer biology, were potent and selective and targeted at genomically defined subsets of cancer patients. The company was developing and implementing a biomarker strategy for each asset.
Solution:
Alacrita placed a board-certified oncologist with several years of drug development experience in the biotech environment as interim chief medical officer in the company. He spent significant time on-site per week at the client’s premises and embedded himself into the team to ensure a high impact engagement. Having ultimate responsibility for the clinical team at the company, he had diverse responsibilities.Key responsibilities included:
- leading the oncology clinical team
- helping recruit and retain additional medical talent
- advising the CEO on strategic clinical decisions
- representing the company at investor, partnering and investigator meetings
Clinical Development Expertise
Leverage the skills and experience of our seasoned drug development physicians to refine your clinical strategy and operations.
Back